<DOC>
	<DOCNO>NCT02415699</DOCNO>
	<brief_summary>Stage III colorectal cancer constitute half colorectal patient , prognosis improve much recently although varies adjuvant drug try . DC-CIK immunotherapy prove improve survival cancer patient , role stage III colorectal cancer patient stain unclear . The investigator study focus efficacy safety DC-CIK immunotherapy plus chemotherapy adjuvant treatment stage III colorectal cancer , compare chemotherapy alone .</brief_summary>
	<brief_title>DC-CIK Immunotherapy Plus Chemotherapy v Chemotherapy Alone Adjuvant Treatment Stage III Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Stage III colon cancer Undergone complete resection primary tumor Completed standard adjuvant chemotherapy ECOG performancer status 02 Adequate hematologic , hepatic renal function HIV positive Immunodeficiency disease Uncontrolled hypertension History recent cancer past 5 year Patients previous concurrent malignancy anticancer therapy Patients allergic platinum drug fluorouracil Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>